Author pages are created from data sourced from our academic publisher partnerships and public sources.
- Publications
- Influence
VLCAD deficiency: pitfalls in newborn screening and confirmation of diagnosis by mutation analysis.
- A. Boneh, B. Andresen, +5 authors J. Pitt
- Biology, Medicine
- Molecular genetics and metabolism
- 1 June 2006
We diagnosed six newborn babies with very long-chain acyl-CoA dehydrogenase deficiency (VLCADD) through newborn screening in three years in Victoria (prevalence rate: 1:31,500). We identified seven… Expand
Markedly elevated neonatal immunoreactive trypsinogen levels in the absence of cystic fibrosis gene mutations is not an indication for further testing
- J. Massie, L. Curnow, N. Tzanakos, I. Francis, C. Robertson
- Medicine
- Archives of Disease in Childhood
- 1 March 2006
Aims: To investigate the immunoreactive trypsinogen (IRT) values above the usual 99th centile laboratory cut-off and determine the value of offering further testing to those infants with a markedly… Expand
Newborn screening for guanidinoacetate methyl transferase deficiency.
- J. Pitt, N. Tzanakos, T. Nguyen
- Medicine
- Molecular genetics and metabolism
- 1 March 2014
4-hydroxyglutamate is a biomarker for primary hyperoxaluria type 3.
- J. Pitt, F. Willis, N. Tzanakos, R. Belostotsky, Y. Frishberg
- Medicine
- JIMD reports
- 2015
Primary hyperoxaluria type 3 (PH3) is a recently identified inborn error of 4-hydroxyproline metabolism causing kidney stone disease. Diagnosis to date has relied on mutation detection. The excretion… Expand
An audit of newborn screening procedure: impact on infants presenting clinically before results are available.
- G. Tal, J. Pitt, Sally Morrisy, N. Tzanakos, A. Boneh
- Medicine
- Molecular genetics and metabolism
- 1 March 2015
BACKGROUND AND OBJECTIVE
Tandem mass spectrometry-based newborn screening (NBS) is a powerful screening tool. The NBS process includes sample collection, shipment, testing, analysis, reporting and… Expand
Biochemical and molecular characteristics of patients with organic acidaemias and urea cycle disorders identified through newborn screening.
- M. Barends, J. Pitt, S. Morrissy, N. Tzanakos, A. Boneh
- Chemistry, Medicine
- Molecular genetics and metabolism
- 1 September 2014
BACKGROUND
In recent years it has become clear that newborn screening (NBS) programmes using tandem mass spectrometry identify "patients" with "classical" inborn errors of metabolism who are… Expand